A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Recruiting

Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor:

AstraZeneca

Code:

NCT05877599

Conditions

Non-small Cell Lung Cancer

Head and Neck Squamous Cell Carcinoma

Colorectal Carcinoma

Pancreatic Adenocarcinoma

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autologous, engineered T Cells targeting TP53 R175H

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-01. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-05-28.